Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Judge Rejects Prior Restraint For Tylenol Ads Ahead Of 'Bellwether' Trial

This article was originally published in The Tan Sheet

Executive Summary

J&J/McNeil may continue to advertise the Tylenol line ahead of the first case in multi-district litigation claiming use of the products as labeled is linked to liver damage, says a federal judge. The plaintiff asked the court to prohibit the firm from advertising that could taint the juror pool ahead of the fall trial.

You may also be interested in...



In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor

Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.

In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor

Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.

J&J Argument Against Liver Damage Experts 'Borders On Ridiculous' – Judge

J&J fails in request to exclude two experts for the plaintiff in bellwether litigation alleging liver damage from indicated doses of Tylenol Extra Strength. The decision represents the second blow in less than a month in J&J's efforts to exclude plaintiff's evidence from the trial.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel